866 related articles for article (PubMed ID: 30297397)
1. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Kowanetz M; Zou W; Gettinger SN; Koeppen H; Kockx M; Schmid P; Kadel EE; Wistuba I; Chaft J; Rizvi NA; Spigel DR; Spira A; Hirsch FR; Cohen V; Smith D; Boyd Z; Miley N; Flynn S; Leveque V; Shames DS; Ballinger M; Mocci S; Shankar G; Funke R; Hampton G; Sandler A; Amler L; Mellman I; Chen DS; Hegde PS
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10119-E10126. PubMed ID: 30297397
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Peters S; Gettinger S; Johnson ML; Jänne PA; Garassino MC; Christoph D; Toh CK; Rizvi NA; Chaft JE; Carcereny Costa E; Patel JD; Chow LQM; Koczywas M; Ho C; Früh M; van den Heuvel M; Rothenstein J; Reck M; Paz-Ares L; Shepherd FA; Kurata T; Li Z; Qiu J; Kowanetz M; Mocci S; Shankar G; Sandler A; Felip E
J Clin Oncol; 2017 Aug; 35(24):2781-2789. PubMed ID: 28609226
[TBL] [Abstract][Full Text] [Related]
3. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
7. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B; Baker B; Kowanetz M; Boone J; Menzl I; Bruey JM; Fine G; Mariathasan S; McCaffery I; Mocci S; Rost S; Smith D; Dennis E; Tang SY; Damadzadeh B; Walker E; Hegde PS; Williams JA; Koeppen H; Boyd Z
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):92-100. PubMed ID: 29346180
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
9. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
[TBL] [Abstract][Full Text] [Related]
10. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Boothman AM; Scott M; Ratcliffe M; Whiteley J; Dennis PA; Wadsworth C; Sharpe A; Rizvi NA; Garassino MC; Walker J
J Thorac Oncol; 2019 Aug; 14(8):1390-1399. PubMed ID: 31063864
[TBL] [Abstract][Full Text] [Related]
11. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
13.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab for the treatment of non-small cell lung cancer.
Santini FC; Rudin CM
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):935-945. PubMed ID: 28714780
[TBL] [Abstract][Full Text] [Related]
15. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
16. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
17. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
[TBL] [Abstract][Full Text] [Related]
18. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
19. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
